hTERT promoter methylation in meningiomas and central nervous hemangiopericytomas

hTERT promoter methylation in pituitary adenomas

(2015) Michaela Köchling et al.   Brain Tumor Pathology

Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation

(2015) Dong-Sheng Huang et al.   EUROPEAN JOURNAL OF CANCER

TERT Promoter Mutations and Risk of Recurrence in Meningioma

(2015) Felix Sahm et al.   JNCI-Journal of the National Cancer Institute

The DNA methylation inhibitor induces telomere dysfunction and apoptosis of leukemia cells that is attenuated by telomerase over-expression

(2015) Xiaolu Zhang et al.   Oncotarget

TERT Promoter Mutations and Risk of Recurrence in Meningioma

(2015) Felix Sahm et al.   JNCI-Journal of the National Cancer Institute

ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples

(2015) Jinquan Cai et al.   Oncotarget

Expression level of hTERT is regulated by somatic mutation and common single nucleotide polymorphism at promoter region in glioblastoma

(2015) Chul-Kee Park et al.   Oncotarget

Methylation of the hTERT promoter is frequent in choroid plexus tumors but not of independent prognostic value

(2014) Vincent Ruland et al.   JOURNAL OF NEURO-ONCOLOGY

Prognostic significance of telomere maintenance mechanisms in pediatric high-grade gliomas

(2014) Kathleen Dorris et al.   JOURNAL OF NEURO-ONCOLOGY

5-aza-2′-deoxycytidine-mediated c-myc Down-regulation Triggers Telomere-dependent Senescence by Regulating Human Telomerase Reverse Transcriptase in Chronic Myeloid Leukemia

(2014) Cindy Grandjenette et al.   NEOPLASIA

ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis

(2013) Benedikt Wiestler et al.   ACTA NEUROPATHOLOGICA

TERT promoter mutations rather than methylation are the main mechanism for TERT upregulation in adult gliomas

(2013) Hideyuki Arita et al.   ACTA NEUROPATHOLOGICA

Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss

(2013) Hideyuki Arita et al.   ACTA NEUROPATHOLOGICA

Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system

(2013) Christian Koelsche et al.   ACTA NEUROPATHOLOGICA

High Incidence of ActivatingTERTPromoter Mutations in Meningiomas Undergoing Malignant Progression

(2013) Stéphane Goutagny et al.   BRAIN PATHOLOGY

Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study

(2013) Pedro Castelo-Branco et al.   LANCET ONCOLOGY

Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia

(2013) E H Estey   LEUKEMIA

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

(2013) P. J. Killela et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Molecular and Morphologic Correlates of the Alternative Lengthening of Telomeres Phenotype in High-Grade Astrocytomas

(2012) Doreen N. Nguyen et al.   BRAIN PATHOLOGY

Differential TERT promoter methylation and response to 5-aza-2′-deoxycytidine in acute myeloid leukemia cell lines: TERT expression, telomerase activity, telomere length, and cell death

(2012) Kerry A. Pettigrew et al.   GENES CHROMOSOMES & CANCER

Alpha anomer of 5-aza-2′-deoxycytidine down-regulates hTERT mRNA expression in human leukemia HL-60 cells

(2007) Miroslav Hájek et al.   BIOCHEMICAL PHARMACOLOGY